Global (United States, European Union and China) Antiemetic Drugs

Antiemetic Drugs Comprehensive Study by Type (Dopamine Antagonist, 5-HT-3 Receptor Antagonist, NK1 Receptor Antagonist, Cannabinoid Receptor Antagonist), Application (Chemotherapy, Gastroenteritis, Surgery), End Use (Hospitals, Medical Research Center, Pharmaceutical Factory, Others) Players and Region - Global Market Outlook to 2025

Antiemetic Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Antiemetic Drugs Market Overview:
Antiemetic drugs are those that have the ability to treat conditions such as nausea and vomiting. They can be used to treat the aforementioned conditions caused by a range of illnesses. Chemotherapy for cancer patients, food poisoning, gastroenteritis, motion sickness, and so on can be treated by antiemetic drugs. In the case of pregnant women, these drugs bring significant relief to women who have to endure bouts of morning sickness, either during the early phase of the pregnancy. For some women, the morning sickness lasts for much longer and antiemetic drugs are extremely useful in such situations. Some of the players profiled in the study are GlaxoSmithKline (United Kingdom), Johnson & Johnson (United States), Pfizer (United States), Sanofi (France), Abbott (United States), Bristol-Myers Squibb (United States), Cipla (India), Eisai (Japan), Eli Lilly (United States) and Glenmark (India).

On the basis of geography, the market of Antiemetic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Hospitals will boost the Antiemetic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing usage of drugs to treat the side effects of other medications including opioid analgesics, chemotherapy, and general anesthetics
  • The Increasing number of patients suffering from cancer and an increased number of surgeries

Influencing Trend
  • Advancement in medical sector

Restraints
  • Lack of suitable animal model that is set to mimic the human responses to antiemetic therapy

Opportunities
  • Emerging economies opening new opportunities for market

Challenges
  • Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners


In November 2018, LGM Pharma, an API (active pharmaceutical ingredients) and procurement specialist acquired Zeta for an amount undisclosed which helped LGM Pharma to broaden its portfolio of products offering to better serve the pharmaceutical industry with a broad range of drugs and complimentary services.


The global antiemetic treatment market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability.

Target Audience:
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Antiemetic Drugs Manufacturers, Suppliers and Distributors, Government Regulatory and Research Organizations and End-Use Industries

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Antiemetic Drugs market on the basis of product [Dopamine Antagonist, 5-HT-3 Receptor Antagonist, NK1 Receptor Antagonist and Cannabinoid Receptor Antagonist] , application [Chemotherapy, Gastroenteritis and Surgery], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Antiemetic Drugs market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Antiemetic Drugs industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Helsinn Healthcare, Heron Therapeutics, IPCA Laboratories, Lupin and Merck.
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Antiemetic Drugs market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Dopamine Antagonist
  • 5-HT-3 Receptor Antagonist
  • NK1 Receptor Antagonist
  • Cannabinoid Receptor Antagonist
By Application
  • Chemotherapy
  • Gastroenteritis
  • Surgery
By End Use
  • Hospitals
  • Medical Research Center
  • Pharmaceutical Factory
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing usage of drugs to treat the side effects of other medications including opioid analgesics, chemotherapy, and general anesthetics
      • 3.2.2. The Increasing number of patients suffering from cancer and an increased number of surgeries
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners
    • 3.4. Market Trends
      • 3.4.1. Advancement in medical sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antiemetic Drugs, by Type, Application, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antiemetic Drugs (Value)
      • 5.2.1. Global Antiemetic Drugs by: Type (Value)
        • 5.2.1.1. Dopamine Antagonist
        • 5.2.1.2. 5-HT-3 Receptor Antagonist
        • 5.2.1.3. NK1 Receptor Antagonist
        • 5.2.1.4. Cannabinoid Receptor Antagonist
      • 5.2.2. Global Antiemetic Drugs by: Application (Value)
        • 5.2.2.1. Chemotherapy
        • 5.2.2.2. Gastroenteritis
        • 5.2.2.3. Surgery
      • 5.2.3. Global Antiemetic Drugs by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Medical Research Center
        • 5.2.3.3. Pharmaceutical Factory
        • 5.2.3.4. Others
      • 5.2.4. Global Antiemetic Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antiemetic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eisai (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Glenmark (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antiemetic Drugs Sale, by Type, Application, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antiemetic Drugs (Value)
      • 7.2.1. Global Antiemetic Drugs by: Type (Value)
        • 7.2.1.1. Dopamine Antagonist
        • 7.2.1.2. 5-HT-3 Receptor Antagonist
        • 7.2.1.3. NK1 Receptor Antagonist
        • 7.2.1.4. Cannabinoid Receptor Antagonist
      • 7.2.2. Global Antiemetic Drugs by: Application (Value)
        • 7.2.2.1. Chemotherapy
        • 7.2.2.2. Gastroenteritis
        • 7.2.2.3. Surgery
      • 7.2.3. Global Antiemetic Drugs by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Medical Research Center
        • 7.2.3.3. Pharmaceutical Factory
        • 7.2.3.4. Others
      • 7.2.4. Global Antiemetic Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antiemetic Drugs: by Type(USD Million)
  • Table 2. Antiemetic Drugs Dopamine Antagonist , by Region USD Million (2015-2020)
  • Table 3. Antiemetic Drugs 5-HT-3 Receptor Antagonist , by Region USD Million (2015-2020)
  • Table 4. Antiemetic Drugs NK1 Receptor Antagonist , by Region USD Million (2015-2020)
  • Table 5. Antiemetic Drugs Cannabinoid Receptor Antagonist , by Region USD Million (2015-2020)
  • Table 6. Antiemetic Drugs: by Application(USD Million)
  • Table 7. Antiemetic Drugs Chemotherapy , by Region USD Million (2015-2020)
  • Table 8. Antiemetic Drugs Gastroenteritis , by Region USD Million (2015-2020)
  • Table 9. Antiemetic Drugs Surgery , by Region USD Million (2015-2020)
  • Table 10. Antiemetic Drugs: by End Use(USD Million)
  • Table 11. Antiemetic Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 12. Antiemetic Drugs Medical Research Center , by Region USD Million (2015-2020)
  • Table 13. Antiemetic Drugs Pharmaceutical Factory , by Region USD Million (2015-2020)
  • Table 14. Antiemetic Drugs Others , by Region USD Million (2015-2020)
  • Table 15. South America Antiemetic Drugs, by Country USD Million (2015-2020)
  • Table 16. South America Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 17. South America Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 18. South America Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 19. Brazil Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 20. Brazil Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 21. Brazil Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 22. Argentina Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 23. Argentina Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 24. Argentina Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 25. Rest of South America Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 27. Rest of South America Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 28. Asia Pacific Antiemetic Drugs, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 32. China Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 33. China Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 34. China Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 35. Japan Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 36. Japan Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 37. Japan Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 38. India Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 39. India Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 40. India Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 41. South Korea Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 42. South Korea Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 43. South Korea Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 44. Taiwan Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 45. Taiwan Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 46. Taiwan Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 47. Australia Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 48. Australia Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 49. Australia Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 53. Europe Antiemetic Drugs, by Country USD Million (2015-2020)
  • Table 54. Europe Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 55. Europe Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 56. Europe Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 57. Germany Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 58. Germany Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 59. Germany Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 60. France Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 61. France Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 62. France Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 63. Italy Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 64. Italy Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 65. Italy Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 66. United Kingdom Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 67. United Kingdom Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 68. United Kingdom Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 69. Netherlands Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 70. Netherlands Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 71. Netherlands Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 72. Rest of Europe Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 73. Rest of Europe Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 74. Rest of Europe Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 75. MEA Antiemetic Drugs, by Country USD Million (2015-2020)
  • Table 76. MEA Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 77. MEA Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 78. MEA Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 79. Middle East Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 80. Middle East Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 81. Middle East Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 82. Africa Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 83. Africa Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 84. Africa Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 85. North America Antiemetic Drugs, by Country USD Million (2015-2020)
  • Table 86. North America Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 87. North America Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 88. North America Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 89. United States Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 90. United States Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 91. United States Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 92. Canada Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 93. Canada Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 94. Canada Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 95. Mexico Antiemetic Drugs, by Type USD Million (2015-2020)
  • Table 96. Mexico Antiemetic Drugs, by Application USD Million (2015-2020)
  • Table 97. Mexico Antiemetic Drugs, by End Use USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Antiemetic Drugs: by Type(USD Million)
  • Table 109. Antiemetic Drugs Dopamine Antagonist , by Region USD Million (2021-2026)
  • Table 110. Antiemetic Drugs 5-HT-3 Receptor Antagonist , by Region USD Million (2021-2026)
  • Table 111. Antiemetic Drugs NK1 Receptor Antagonist , by Region USD Million (2021-2026)
  • Table 112. Antiemetic Drugs Cannabinoid Receptor Antagonist , by Region USD Million (2021-2026)
  • Table 113. Antiemetic Drugs: by Application(USD Million)
  • Table 114. Antiemetic Drugs Chemotherapy , by Region USD Million (2021-2026)
  • Table 115. Antiemetic Drugs Gastroenteritis , by Region USD Million (2021-2026)
  • Table 116. Antiemetic Drugs Surgery , by Region USD Million (2021-2026)
  • Table 117. Antiemetic Drugs: by End Use(USD Million)
  • Table 118. Antiemetic Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 119. Antiemetic Drugs Medical Research Center , by Region USD Million (2021-2026)
  • Table 120. Antiemetic Drugs Pharmaceutical Factory , by Region USD Million (2021-2026)
  • Table 121. Antiemetic Drugs Others , by Region USD Million (2021-2026)
  • Table 122. South America Antiemetic Drugs, by Country USD Million (2021-2026)
  • Table 123. South America Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 124. South America Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 125. South America Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 126. Brazil Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 127. Brazil Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 128. Brazil Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 129. Argentina Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 130. Argentina Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 131. Argentina Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 132. Rest of South America Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 133. Rest of South America Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 134. Rest of South America Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 135. Asia Pacific Antiemetic Drugs, by Country USD Million (2021-2026)
  • Table 136. Asia Pacific Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 137. Asia Pacific Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 138. Asia Pacific Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 139. China Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 140. China Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 141. China Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 142. Japan Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 143. Japan Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 144. Japan Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 145. India Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 146. India Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 147. India Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 148. South Korea Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 149. South Korea Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 150. South Korea Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 151. Taiwan Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 152. Taiwan Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 153. Taiwan Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 154. Australia Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 155. Australia Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 156. Australia Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 160. Europe Antiemetic Drugs, by Country USD Million (2021-2026)
  • Table 161. Europe Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 162. Europe Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 163. Europe Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 164. Germany Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 165. Germany Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 166. Germany Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 167. France Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 168. France Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 169. France Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 170. Italy Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 171. Italy Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 172. Italy Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 173. United Kingdom Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 174. United Kingdom Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 175. United Kingdom Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 176. Netherlands Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 177. Netherlands Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 178. Netherlands Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 179. Rest of Europe Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 180. Rest of Europe Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 181. Rest of Europe Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 182. MEA Antiemetic Drugs, by Country USD Million (2021-2026)
  • Table 183. MEA Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 184. MEA Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 185. MEA Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 186. Middle East Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 187. Middle East Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 188. Middle East Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 189. Africa Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 190. Africa Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 191. Africa Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 192. North America Antiemetic Drugs, by Country USD Million (2021-2026)
  • Table 193. North America Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 194. North America Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 195. North America Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 196. United States Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 197. United States Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 198. United States Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 199. Canada Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 200. Canada Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 201. Canada Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 202. Mexico Antiemetic Drugs, by Type USD Million (2021-2026)
  • Table 203. Mexico Antiemetic Drugs, by Application USD Million (2021-2026)
  • Table 204. Mexico Antiemetic Drugs, by End Use USD Million (2021-2026)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antiemetic Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Antiemetic Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Antiemetic Drugs: by End Use USD Million (2015-2020)
  • Figure 7. South America Antiemetic Drugs Share (%), by Country
  • Figure 8. Asia Pacific Antiemetic Drugs Share (%), by Country
  • Figure 9. Europe Antiemetic Drugs Share (%), by Country
  • Figure 10. MEA Antiemetic Drugs Share (%), by Country
  • Figure 11. North America Antiemetic Drugs Share (%), by Country
  • Figure 12. Global Antiemetic Drugs share by Players 2020 (%)
  • Figure 13. Global Antiemetic Drugs share by Players (Top 3) 2020(%)
  • Figure 14. Global Antiemetic Drugs share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2020
  • Figure 22. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi (France) Revenue: by Geography 2020
  • Figure 24. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 25. Abbott (United States) Revenue: by Geography 2020
  • Figure 26. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 28. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 29. Cipla (India) Revenue: by Geography 2020
  • Figure 30. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Eisai (Japan) Revenue: by Geography 2020
  • Figure 32. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 34. Glenmark (India) Revenue, Net Income and Gross profit
  • Figure 35. Glenmark (India) Revenue: by Geography 2020
  • Figure 36. Global Antiemetic Drugs: by Type USD Million (2021-2026)
  • Figure 37. Global Antiemetic Drugs: by Application USD Million (2021-2026)
  • Figure 38. Global Antiemetic Drugs: by End Use USD Million (2021-2026)
  • Figure 39. South America Antiemetic Drugs Share (%), by Country
  • Figure 40. Asia Pacific Antiemetic Drugs Share (%), by Country
  • Figure 41. Europe Antiemetic Drugs Share (%), by Country
  • Figure 42. MEA Antiemetic Drugs Share (%), by Country
  • Figure 43. North America Antiemetic Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Johnson & Johnson (United States)
  • Pfizer (United States)
  • Sanofi (France)
  • Abbott (United States)
  • Bristol-Myers Squibb (United States)
  • Cipla (India)
  • Eisai (Japan)
  • Eli Lilly (United States)
  • Glenmark (India)
Additional players considered in the study are as follows:
Helsinn Healthcare , Heron Therapeutics , IPCA Laboratories , Lupin , Merck
Select User Access Type

Key Highlights of Report


Mar 2021 225 Pages 85 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Antiemetic Drugs Quantitative research analysis
Global (United States, European Union and China) Antiemetic Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global (United States, European Union and China) Antiemetic Drugs Report?

Have a Query? Click Here

Other Related Reports

Antipsychotic Drugs Comprehensive Study by Type (First Antipsychotic Drugs (Typical Antipsychotics), Second Antipsychotic Drugs (Newer Drugs), Third Antipsychotic Drugs), Application (Schizophrenia, ...
$ 3650
Narcolepsy Drug Comprehensive Study by Type (Antioxidants Type, Stimulants Type, Other), Application (Daytime Extreme Sleepiness, Cataplexia, Others), Narcolepsy Type (Type 1 Narcolepsy, Type 2 Narco...
$ 3750
Rosuvastatin Calcium Comprehensive Study by Type (Purity 98.0%, Purity 99.0%, Other), Application (Capsule, Gel, Tablet), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmaci...
$ 3500
Krill Oil Comprehensive Study by Type (Liquid, Tablet), Application (Dietary Supplements, Pet and Animal Food, Food and Beverages, Pharmaceuticals), Distribution Channel (Offline, Online), Packaging ...
$ 3500
Codeine Phosphate Comprehensive Study by Type (Extracted from Opium, Synthesized by Morphine), Application (Narcotic Analgesic, Antitussive, Others), End-users (Hospitals, Clinics, Others), Distribut...
$ 3450
Active Pharmaceutical Ingredient Comprehensive Study by Type (Innovative, Generic), Application (Chemical, Deodorant, Others) Players and Region - Global Market Outlook to 2027
$ 3500